Immunosuppressants in Organ Transplantation

Area of Science:

• Nephrology
• Immunology
• Pediatric Medicine

Background:

• Post-transplant immunosuppression aims to prevent acute and chronic rejection in pediatric renal transplant recipients.
• Current therapies lack immunological specificity, necessitating a balance to avoid overimmunosuppression and its associated risks (infection, cancer).
• Many immunosuppressive strategies for kidney transplants are applicable to other pediatric solid organ transplants (liver, heart).

Purpose of the Study:

• To discuss immunosuppressive therapy in pediatric renal transplant recipients.
• To highlight the challenges and considerations specific to immunosuppression in children.
• To review current maintenance immunosuppressive agents and their combinations.

Main Methods:

• Review of current maintenance immunosuppressive agents: tacrolimus, cyclosporine, mycophenolate mofetil, azathioprine, everolimus, sirolimus, and glucocorticoids.
• Consideration of data from adult renal transplantation trials adapted for pediatric use.
• Focus on unique pediatric dosage requirements and clinical effects, including impact on growth and development.

Main Results:

• Major maintenance immunosuppressive agents include tacrolimus, cyclosporine, mycophenolate mofetil, azathioprine, everolimus, sirolimus, and glucocorticoids.
• Pediatric immunosuppressive therapy requires modifications due to children's unique responses and developmental considerations.
• Optimal immunosuppressive therapy post-transplant is not yet definitively established.

Conclusions:

• The goal of immunosuppressive therapy is to optimize allograft survival by preventing rejection while minimizing drug toxicities.
• Careful balancing of immunosuppressive agents is required to prevent graft rejection and reduce risks of infection and cancer.
• Further research is needed to establish the optimal immunosuppressive regimens for pediatric renal transplant recipients.